1. Home
  2. MKTW vs LGVN Comparison

MKTW vs LGVN Comparison

Compare MKTW & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$17.65

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.87

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
LGVN
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
34.0M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MKTW
LGVN
Price
$17.65
$0.87
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$20.00
$3.00
AVG Volume (30 Days)
24.9K
814.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
10.33%
N/A
EPS Growth
1183.33
50.76
EPS
2.31
N/A
Revenue
$512,403,000.00
$709,000.00
Revenue This Year
$1.52
N/A
Revenue Next Year
$4.55
$10.81
P/E Ratio
$7.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.65
$0.48
52 Week High
$21.74
$1.80

Technical Indicators

Market Signals
Indicator
MKTW
LGVN
Relative Strength Index (RSI) 55.90 38.96
Support Level $16.06 $0.74
Resistance Level $20.62 $0.99
Average True Range (ATR) 0.87 0.07
MACD -0.04 -0.04
Stochastic Oscillator 77.84 0.63

Price Performance

Historical Comparison
MKTW
LGVN

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: